ArticleActa biomaterialia2015
S-Nitrosothiol-modified nitric oxide-releasing chitosan oligosaccharides as antibacterial agents.
Article in Acta biomaterialia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 76 citations in OpenAlex.
- Enhanced Nitric Oxide Delivery Through Self-Assembling Nanoparticles for Eradicating Gram-Negative Bacteria.Advanced healthcare materials · 2024Article
- Nitric oxide releasing coatings for the prevention of viral and bacterial infections.Biomaterials science · 2024Article
- Functionalized MoSJournal of nanobiotechnology · 2023Article
- Nitric Oxide-Induced Morphological Changes to Bacteria.ACS infectious diseases · 2023Article
- Injectable polysaccharide hydrogels as localized nitric oxide delivery formulations.Advanced materials technologies · 2023Article
- Recent Developments in Nitric Oxide Donors and Delivery for Antimicrobial and Anti-Biofilm Applications.Molecules (Basel, Switzerland) · 2022Review
- Β-Cyclodextrin-graft-poly(amidoamine) dendrons as the nitric oxide deliver system for the chronic rhinosinusitis therapy.Drug delivery · 2021Article
- Therapeutic Delivery of Nitric Oxide Utilizing Saccharide-Based Materials.ACS applied materials & interfaces · 2021Review
- Modulation of the lifespan ofChemical science · 2020Article
- The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications.Biochemical pharmacology · 2020Review
- Mode of nitric oxide delivery affects antibacterial action.ACS biomaterials science & engineering · 2020Article
- Nitric Oxide-Releasing Polymeric Materials for Antimicrobial Applications: A Review.Antioxidants (Basel, Switzerland) · 2019Review
- Antibiofilm Efficacy of Nitric Oxide-Releasing Alginates against Cystic Fibrosis Bacterial Pathogens.ACS infectious diseases · 2019Article
- Nitric oxide-releasing alginates as mucolytic agents.ACS biomaterials science & engineering · 2019Article
- Nitric Oxide (NO)-Releasing Macromolecules: Rational Design and Biomedical Applications.Frontiers in chemistry · 2019Review
- Article
- Achieving Long-Term Biocompatible Silicone via Covalently Immobilized S-Nitroso- N-acetylpenicillamine (SNAP) That Exhibits 4 Months of Sustained Nitric Oxide Release.ACS applied materials & interfaces · 2018Article
- Nitric Oxide-Releasing Macromolecular Scaffolds for Antibacterial Applications.Advanced healthcare materials · 2018Review
- Nitric Oxide-Releasing Alginates.Biomacromolecules · 2018Article
- A pH-Sensing Optode for Mapping Spatiotemporal Gradients in 3D Paper-Based Cell Cultures.Analytical chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
S-Nitrosothiol-modified chitosan oligosaccharides were synthesized by reaction with 2-iminothiolane hydrochloride and 3-acetamido-4,4-dimethylthietan-2-one, followed by thiol nitrosation. The resulting nitric oxide (NO)-releasing chitosan oligosaccharides stored ∼0.3μmol NO mg(-1) chitosan. Both the chemical structure of the nitrosothiol (i.e. primary and tertiary) and the use of ascorbic acid as a trigger for NO donor decomposition were used to control the NO-release kinetics. With ascorbic acid, the S-nitrosothiol-modified chitosan oligosaccharides elicited a 4-log reduction in Pseudomonas aeruginosa viability. Confocal microscopy indicated that the primary S-nitrosothiol-modified chitosan oligosaccharides associated more with the bacteria relative to the tertiary S-nitrosothiol system. The primary S-nitrosothiol-modified chitosan oligosaccharides elicited minimal toxicity towards L929 mouse fibroblast cells at the concentration necessary for a 4-log reduction in bacterial viability, further demonstrating the potential of S-nitrosothiol-modified chitosan oligosaccharides as NO-release therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.